Zimmer Biomet Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated July 13, 2016, reports the completion of a tender offer and subsequent merger by Zimmer Biomet Holdings, Inc. ("Parent") to acquire LDR Holding Corporation ("LDR"). The transaction was executed pursuant to an Agreement and Plan of Merger dated June 6, 2016.
Key Financial Metrics and Transaction Details
- Offer Price: $37.00 per share in cash.
- Shares Tendered: 24,278,729 shares (approximately 82.7% of outstanding shares) were validly tendered and not withdrawn.
- Guaranteed Delivery: Notices were delivered for 1,826,189 shares (approximately 6.2% of outstanding shares).
- Total Consideration: Approximately $1.1 billion (excluding transaction fees and expenses).
- Post-Merger Status: LDR became an indirect wholly-owned subsidiary of Zimmer Biomet.
Material Changes and Transaction Mechanics
The tender offer expired on July 13, 2016. Upon satisfaction of the minimum tender condition, Merger Sub accepted all validly tendered shares for payment. Immediately following acceptance, Merger Sub merged with and into LDR under Section 251(h) of the Delaware General Corporation Law.
Key conversion terms for LDR equity holders included:
- Common Stock: Converted to the right to receive the Offer Price ($37.00), less applicable taxes.
- Restricted Stock Units (RSUs) & Performance Stock Units (PSUs): Became fully vested and converted to cash payments based on the Offer Price.
- Stock Options: Became fully vested; in-the-money options were converted to cash equal to the excess of the Offer Price over the exercise price. Out-of-the-money options were terminated without payment.
- Phantom Units: Converted to cash payments based on the Offer Price.
Outlook, Risks, and Management Commentary
Management announced the expiration of the offer and the completion of the merger via a press release filed as an exhibit to this report. The filing does not provide specific forward-looking financial guidance, liquidity metrics, or risk factors beyond the standard legal disclosures regarding the merger agreement and tax withholdings.
Investor Verification Checklist
- Verify the final settlement of the $1.1 billion aggregate consideration.
- Confirm the treatment of any shares held by dissenting shareholders demanding statutory appraisal under Section 262 of the DGCL.
- Review the impact of the acquisition on Zimmer Biomet's consolidated balance sheet and debt levels in subsequent filings (e.g., 10-Q or 10-K).
- Check for any undisclosed transaction fees or expenses that may affect the net cost of the acquisition.